文献速递免疫规划传染病防控与疫情报告

BBIBP-CorV接种者BNT162b2异源加强免疫原性与反应原性研究

Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon.
PubMed 文献 · Vaccine · 2021-10-13

黎巴嫩 pilot 前瞻性队列研究在无COVID-19感染史且已完成两剂BBIBP-CorV接种者中,评估BNT162b2异源加强的安全性及免疫原性,并与同源BNT162b2接种比较。异源加强安全耐受,抗刺突IgG几何平均滴度显著高于同源BNT162b2免疫。

要点

  • BBIBP-CorV接种后BNT162b2异源加强安全且耐受良好。
  • 异源加强抗刺突IgG几何平均滴度显著高于同源BNT162b2免疫。
  • 在mRNA疫苗可及性有限且已接种BBIBP-CorV人群中,混合接种可克服低免疫原性。

核心结论

  • BBIBP-CorV/BNT162b2异源加强安全耐受,且抗刺突IgG几何平均滴度显著高于同源BNT162b2免疫。

研究设计与样本

  • 黎巴嫩贝鲁特Makassed综合医院2021年2月17日至6月30日开展的前瞻性队列研究,纳入无COVID-19感染史且已完成两剂BBIBP-CorV接种者,测试BNT162b2加强针安全性与免疫原性。

主要发现

  • 异源加强安全且耐受良好。
  • 异源加强抗刺突IgG几何平均滴度为8040 BAU/mL(95%CI 4612-14016),同源BNT162b2免疫为1384 BAU/mL(95%CI 1063-1801),P<0.0001。

临床怎么用

  • 在mRNA疫苗可及性有限且人群已接种BBIBP-CorV的国家,可考虑BBIBP-CorV/BNT162b2混合接种以克服BBIBP-CorV单独诱导的低免疫原性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Facing new COVID-19 waves, the effectiveness of BBIBP-CorV has been noted to be low in countries whose populations were already administered two doses of the vaccine. Heterologous vaccination using ChAdOx1-S/BNT162b2 elicited higher immunogenicity compared with homologous immunization. BBIBP-CorV/BNT162b2 combination is worth testing. In this pilot prospective cohort study conducted at Makassed General Hospital, Beirut, Lebanon, from February 17, 2021, to June 30, 2021, we tested the safety and immunogenicity of a BNT162b2 booster dose in COVID-19-naïve individuals who had received two doses of the BBIBP-CorV vaccine. Heterologous booster vaccination was found to be safe and well tolerated. It was significantly associated with higher anti-spike IgG geometric mean titers compared to that after homologous BNT162b2 immunization in COVID-19-naïve individuals [(8040BAU/mL, 95%confidence interval (CI), 4612-14016) vs (1384BAU/mL, 95%CI, 1063-1801), respectively, (P < 0.0001)]. In countries with limited access to mRNA vaccines and where populations have already received BBIBP-CorV, mixing BBIBP-CorV/BNT162b2 is seen to overcome the low immunogenicity induced by BBIBP-CorV alone, thus potentially providing protection against emerging variants.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Moghnieh R, Mekdashi R, El-Hassan S, et al. Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon. Vaccine. 2021. PMID: 34656379. doi:10.1016/j.vaccine.2021.10.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。